Edition:
India

Brainstorm Cell Therapuetics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.45USD
1:30am IST
Change (% chg)

$0.06 (+1.77%)
Prev Close
$3.39
Open
$3.39
Day's High
$3.55
Day's Low
$3.39
Volume
6,810
Avg. Vol
15,140
52-wk High
$5.15
52-wk Low
$2.88

Latest Key Developments (Source: Significant Developments)

Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY.BRAINSTORM CELL THERAPUETICS INC - APPROVAL ADVANCES CO'S APPLICATION TO ISRAEL MOH FOR TREATMENT OF ALS PATIENTS IN ISRAEL FOR A FEE.  Full Article

Brainstorm Cell Therapuetics names Eyal Rubin CFO
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer.Eyal Rubin joins co from Teva Pharmaceutical Industries Ltd.  Full Article

Brainstorm reports Q3 loss per share of $0.13
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm announces third quarter 2017 financial results.Q3 loss per share $0.13.  Full Article

Brainstorm cell Q2 loss per share $0.05
Thursday, 11 Aug 2016 

Brainstorm Cell Therapuetics Inc ::.  Full Article

Brainstorm Cell Therapeutics reports Q1 loss of $0.10 per share
Tuesday, 10 May 2016 

Brainstorm Cell Therapuetics Inc : Brainstorm cell therapeutics reports first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.10.  Full Article

BRIEF-Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health

* BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY